Susceptibility Pattern of Enterococcal Isolates in a Tertiary Care Hospital against Tigecycline, Linezolid and Teicoplanin

There has been an upsurge in the emergence of Enterococci as a nosocomial pathogen in the recent years. The emergence of vancomycin-resistant enterococci (VRE) is a cause of concern, and is very difficult to control. A study on the speciation and antimicrobial susceptibility pattern of Linezolid, Teicoplanin and Tigecycline isolated of from clinical specimens from patients in the Department of Microbiology, MGUMST was carried out in the period of January 2018 to December 2018. A total of 172 enterococcal isolates obtained from various clinical samples were included in the study. Identification and antimicrobial susceptibility testing was done on Vitek-2 Compact (bioMérieux) E. facealis (54.97%) was the predominant enterococcal species isolated followed by E. faecium (39.76%). The isolates were shown to have 5.84% resistance to Linezolid, 13.45% resistance to Teicoplanin and 100% sensitivity to Tigecycline. This study was performed to seek an alternative option like Linezolid, Tigecycline and Teicoplanin as vancomycin is reportedly being noted resistant in many clinical cases.